Founded in 1987, Merit Medical manufactures medical devices used in interventional, diagnostic, and therapeutic procedures across radiology, cardiology, breast, vascular, and dialysis specialties. Locally, Merit Medical Australia opened for business in 2016 with an office in Melbourne, followed by an office in Auckland in 2017. Merit Medical ANZ is dedicated to supplying and supporting our customers with best-in-class innovative products, dedicated education offerings, and our commitment to social and environmental responsibility.
For more information, please visit: www.merit.com

Icon is a leading cancer care organisation with centres across Australia and globally in New Zealand, Singapore, Indonesia, Malaysia, China and the UK. We deliver integrated medical oncology, haematology, radiation oncology, molecular imaging, theranostics and clinical research, aiming to provide the best care possible close to home. Icon Cancer Centre Australia brings together 250+ specialists across 45 centres, offering multidisciplinary expertise. We provide comprehensive breast cancer treatment, including chemotherapy, hormone and targeted therapies, supported by advanced radiation techniques such as stereotactic approaches, SGRT for tattooless positioning and DIBH for improved patient outcomes. Our teams are committed to personalised, high-quality care.
LinkedIn: @Icon Cancer Centre – Australia & New Zealand
For more information, please visit: iconcancercentre.com.au/

Since 1992, Device Technologies has been dedicated to improving patients’ lives through leading edge technology and services. Successfully supplying hospitals and healthcare professionals with the finest medical solutions for their patients, we continue to grow, with over 200 trusted brands over 1000 highly skilled staff throughout Australia, New Zealand, and Asia.
Behind every brand distributed by Device Technologies is the concept that we are delivering leading technology into the most capable hands. We nurture the relationship between distributor and healthcare professionals, guiding the process from concept to delivery and ongoing support with training and technical service specialty teams.
For more information, please visit: www.device.com.au

Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan with over 120 years of innovation, is expanding its Australian presence. Our mission: to redefine cancer treatment through our proprietary antibody drug conjugate (ADC) technology, aiming to become a global top ten in oncology by 2030.
In Australia, we’re building a dedicated team, conducting 18 clinical trials at 47 sites evaluating our DXd ADCs*, and working to bring their benefits to patients sooner. Our pipeline of ADCs and novel entities targets difficult-to-treat cancers including breast, lung, gastric, ovarian, and endometrial. We are committed to partnering with researchers, clinicians, patients, patient advocates and government to deliver our mission.
*does not include other assets

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
For more information, please visit astrazeneca.com.au

Novartis is improving the lives of more than 2.5 million patients across Australia and New Zealand through our medicines. By partnering with the healthcare system we are working for patients to address their needs, and we are committed to accelerating patient access to life saving treatments and associated healthcare.
We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich research pipeline has 50+ ongoing Phase III programs. We are transforming how clinical trials are run to increase patients’ access to our industry-leading clinical trials footprint in Australia.
For more information, please visit: www.novartis.com/au-en/

Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and broadening treatment options for cancer patients. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
For more information, please visit: www.lilly.com/au/

At United Airlines, Good Leads The Way. With U.S. hubs in Chicago, Denver, Houston, Los Angeles, New York/Newark, San Francisco and Washington, D.C., United operates the most comprehensive global route network among North American carriers and is now the largest airline in the world as measured by available seat miles. United has more flights between Australia and the U.S.A. than any other U.S. airline, offering nonstop service from Sydney, Melbourne, Brisbane and seasonally from Adelaide. Plus, United’s partnership with Virgin Australia expands the footprint of departure cities throughout Australia and adds more benefits for both MileagePlus and Velocity Frequent Flyer members. Eligible members can earn and redeem miles/points, receive priority check-in and boarding, and access lounge locations.
For more information please visit united.com

Baylor St. Luke’s Medical Center, a member of CommonSpirit and headquartered in the Texas Medical Center in Houston, is a leading academic medical center within the St. Luke’s Health system, which includes hospitals, physician groups, specialty institutes and one of three comprehensive cancer centers in Texas. Our affiliation with Baylor College of Medicine positions us as a leader and drives our commitment to advancing health care standards through groundbreaking research and the development of advanced treatments found nowhere else.

Sorsix is a specialist digital health company delivering configurable, interoperable healthcare platforms that streamline clinical, administrative, and patient-facing workflows. Our flagship SaaS product, Pinga®, is a no code, modular health platform designed to digitise end to end patient pathways, automate referrals and scheduling, and enhance patient engagement. Built to integrate with national health infrastructure and third party systems, Pinga supports FHIR aligned interoperability and scalable deployments across local, state wide, and national health systems. Sorsix solutions are trusted by public healthcare organisations to reduce wait times, improve access to care, and deliver measurable operational and clinical outcomes.
For more information, please visit: www.sorsix.com

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Based in Melbourne, Gilead Sciences Australia and New Zealand employs over 100 people.
For more information, please visit: www.gilead.com/en-au